Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41
about
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesCrystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external regionDistinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsLongitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodiesOligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodiesAntibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoproteinNeutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation.Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediatesGenetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designHuman Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.HIV-1 membrane fusion: targets of opportunityNeutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionThe long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infectionMultiantibody strategies for HIV.Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion.
P2860
Q24791794-CCE6154A-DCAD-4D97-9B9B-6864355F9E37Q27312171-876E2C30-A48F-4E27-B3D2-ADDF0E32368EQ27469855-33846E38-7050-4209-B52C-E79DEAC16252Q27485578-D4ABAFAD-0135-48E7-BDC1-0440D7CEA172Q27665883-FBE5536C-036D-4E1B-9DD7-554B1150949BQ27665884-E655C23E-6689-46E1-902D-4F3BFE430451Q28469068-21933D68-57E0-4935-AE04-3E023CAF3D59Q28477253-D35491B1-1526-4661-A692-E733172B3BDFQ30436401-A649A1B3-46E2-4AB7-9D1C-2F45B5E2A790Q30843874-5EF78ACC-14D1-45B4-8E86-08A81F39CA87Q31016954-1F4E16A4-136F-4A7C-8476-CC81084709EDQ31016969-DABDFDC4-233B-4EEA-99DB-73D128CBFA9BQ33272711-6F4FEC34-F216-4B59-875B-A7A0C81A9D0DQ33622229-640978E1-4BEC-48E0-B249-16BEAEBEA47DQ33809112-C5A973E7-01C4-4DCF-87C1-70E6397D86E1Q33843696-A1017B7A-BBAF-4876-BA93-1734B07E182AQ33854904-2A7A05CF-6CFE-4C55-9D17-3D5447B62F02Q34085098-BE4087DB-79A9-4D50-B37D-2FDC07F07A21Q34183957-F1AC2C3F-7F6B-453D-AF64-1C39FA00AE49Q34225654-F4611D26-E386-41D0-906D-97B08A08812DQ34341098-2761C1EC-8D94-4496-8934-C6126EEA1061Q34342264-4F1B6BF0-3ACD-4FC6-AFD1-409FE6ADDCD4Q34359035-99023C4D-2637-4F64-A8AC-44138F40EAD9Q34361680-8D5BB81A-8F9E-4D3B-82D2-6271B7070EEAQ34374835-49C17E2C-C832-484B-AF05-282E6E0415D0Q34434753-B5100F8E-44C5-4638-B534-BF7D5DD3F4ACQ34778515-D88E72A6-7F84-48FA-B82B-85D6165476EDQ35168642-6BFBC858-88FD-4E69-B599-8C4EB85A1B09Q35173635-08B997D2-85EA-48F9-8FDA-B4C068887B5EQ35196671-BE3510A2-88E5-4D7D-A3E6-11EB39A1DF7FQ36076117-16D295E0-7FA8-4A8A-BCAA-08617C753708Q36366904-EF657030-46D4-4090-8D46-0ABE7F74B1C5Q36404194-46105784-BAAC-4D61-BDCE-0BF5D18D1A65Q36423897-B1E6DF18-3406-439E-90AC-5BEDFF2F2A36Q36509423-166E0B60-5D71-4B4F-A31A-134C4E23962EQ36954635-35C0D516-3CDF-44C9-83DC-053A4BAB8550Q37002517-97CE73C7-CAD9-476D-85BC-81CC6D7B7D43Q37033417-F29FCDA2-FFB0-4060-B308-4AD680B82D31Q38120526-1CD8828D-6930-4152-8FE0-CF31A01FEC9CQ40127843-3296F477-6C0B-4BEF-8355-354D817D37B8
P2860
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@ast
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@en
type
label
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@ast
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@en
prefLabel
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@ast
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@en
P2860
P1433
P1476
Recognition by human monoclona ...... nodeficiency virus type 1 gp41
@en
P2093
S Zolla-Pazner
P2860
P304
P356
10.1128/JVI.74.13.6186-6192.2000
P577
2000-07-01T00:00:00Z